ASCO Meeting 2020 Participation

Awards

Anne Chiang, M.D., Ph.D., will be honored with the Fellow of the American Society of Clinical Oncology (FASCO) distinction for her extraordinary volunteer service, dedication, and commitment to ASCO.

Yale’s Vikram Jira, M.D., will receive the Pain and Symptom Management Special Merit Award for the highest-ranking abstract in Pain and Symptom Management Research. Ranjan Pathak, MBBS, and Rozalyn L. Rodwin, M.D., are Merit Award Recipients.

Mariya Rozenblit, MD
2020 ASCO Young Investigator Award
“Using single nucleotide variants of high functional importance to predict the risk of developing breast cancer in young women with high risk family history”
Mentored by: Lajos Pusztai, MD

Presentations

Head and Neck Cancer

Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311)
Authors: Robert L. Ferris, Yael Flamand, Gregory S. Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J. Garcia, Christine H. Chung, Maura L. Gillison, Umamaheswar Duvvuri, Bert W. O'malley, Enver Ozer, Giovana R. Thomas, Wayne Koch, Michael Elliot Kupferman, Richard Bryan Bell, Nabil F. Saba, Miriam Lango, Eduardo Mendez, Barbara Burtness
Abstract: 6500
Session: May 30; 10:30 AM

Head and Neck Cancer

KEYNOTE-048: Progression after the next line of therapy following pembrolizumab (P) or P plus chemotherapy (P+C) vs EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
Authors: Kevin Joseph Harrington, Danny Rischin, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto Castro, Amanda Psysri, Neus Baste, Prakash C. Neupane,
**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**

Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial

Authors: Charles S. Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-hee Ryu, Lorenzo Fornaro, Tomasz Olesinski, Christian Caglevic, Hyun C. Chung, Kei Muro, Eric Van Cutsem, Anneli Elme, Peter C. Thuss-Patience, Ian Chau, Atsushi Ohtsu, Pooja Bhagia, Anran Wang, Chie-Schin Shih, Kohei Shitara

Abstract: 4503
Session: May 30; 11:00 AM

**Central Nervous System Tumors**

Randomized phase II study of rituximab, methotrexate (MTX), procarbazine, vincristine, and cytarabine (R-MPV-A) with and without low-dose whole-brain radiotherapy (LD-WBRT) for newly diagnosed primary CNS lymphoma (PCNSL)

Authors: Antonio M. Omuro, Lisa M. DeAngelis, Theodore Karrison, Joe A. Bovi, Marc Rosenblum, Benjamin W. Corn, Denise Correa, Jeffrey S. Wefel, Sanjay Anjea, Christian Grommes, Lauren Schaff, Steven E. Waggner, Enrico C. Lallana, Maria Werner-Wasik, Fabio Iwamoto, Timothy J. Robinson, Eric Donnelly, Timothy Struve, Minhee Won, Minesh P. Mehta

Abstract: 2501
Session: May 30; 11:00 AM

**Plenary Session: Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers**

Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA

Authors: Roy S. Herbst, Masahiro Tsuboi, Thomas John, Christian Grohé, Margarita Majem, Jonathan W. Goldman, Sang-We Kim, Dominika Marmol, Yuri Rukazenkov, Yi-Long Wu

Abstract: LBA5
Session: May 31; 1:00 PM

**Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**

First-in-human phase I study of ARV-110, an androgen receptor (AR) PROTAC degrader in patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC) following enzalutamide (ENZ) and/or abiraterone (ABI)

Authors: Daniel P. Petrylak, Xin Gao, Nicholas J. Vogelzang, Mary H. Garfield, Ian Taylor, Marcia Dougan Moore, Ronald A. Peck, Howard A. Burris III

Abstract: 3500
Session: May 31; 4:00 PM

**Publication Only - Health Services Research and Quality Improvement**

The impact of clinical trial (CTr) participation on savings performance in the oncology care model (OCM)

Authors: Kerin B. Adelson, Maureen Canavan, Sophia Mun, Cary Philip Gross, Naralys Sinanis, Amy J. Davidoff
Abstract: e19367
Publication Only - Gastrointestinal Cancer—Colorectal and Anal

A multi-gene colorectal cancer liquid biopsy with >90% accuracy in diagnosis and assessment of disease status
Authors: Irvin Mark Modlin, Mark S. Kidd, Alexandra Kitz, Ignat A. Drozdov, Anna Malczewska, Katarzyna Kusnierz, Harry Aslanian
Abstract: e16079

Publication Only - Symptoms and Survivorship

With a little help from my friends: A multi-disciplinary approach to cancer survivorship
Authors: Scott Capozza, Maura Harrigan, Javin Brita, Angela Khairallah, Tara B. Sanft
Abstract: e24082

Publication Only - Gastrointestinal Cancer—Colorectal and Anal

Genomic biomarkers to determine survival in Multicenter Study of RAS mutations (MURAS) in patients with colorectal liver metastases receiving Y90 radioembolization treatment
Abstract: e16119

Publication Only - Cancer Prevention, Risk Reduction, and Genetics

Is there an association between air pollution levels and lung cancer incidence?
Authors: Seema Patel, Anees B. Chagpar
Abstract: e13584

Publication Only - Symptoms and Survivorship

The association between initial chemotherapy treatment timing, intensity, and end-of-life (EOL) care trajectory among older adults with advanced stage lung cancer (aLC)
Authors: Carolyn J Presley, Haseeba Shahzad, Maureen Canavan, Elizabeth Horn Prsic, Maureen Saphire, Shi-Yi Wang, Amy J. Davidoff
Abstract: e24009

Publication Only - Symptoms and Survivorship

End-of-life (EOL) trajectories among older adults dying with lung cancer (LC)
Authors: Amy J. Davidoff, Maureen Canavan, Shi-Yi Wang, Elizabeth Horn Prsic, Maureen Saphire, Carolyn J Presley
Abstract: e24008

Publication Only - Health Services Research and Quality Improvement

Multiple myeloma (MM) therapy within a Medicare insured patient population: Role of initial care setting and socioeconomic status
Authors: Amy J. Davidoff, Jessica B. Long, Jan Philipp Bewersdorf, Rory Shallis, Amer Methqal Zeidan, Nikolai Alexandrovich Podoltsev, Rong Wang, Steven Gore, Smith Giri, Natalia Neparidze, Scott F. Huntington
Abstract: e19057
**Publication Only - Care Delivery and Regulatory Policy**
*Utilization of online crowdfunding for alternative cancer treatments at home and abroad*
Authors: Joshua David Gruhl, John Stuart Peterson, Sydney Davis, Jaxon Carey Olsen, Matthew Parsons, Benjamin H Kann, Gregory J. Stoddard, Skyler B Johnson
Abstract: e14044

**Publication Only - Genitourinary Cancer—Prostate, Testicular, and Penile**
*Using longitudinal PSA values and machine learning for predicting progression of early stage prostate cancer in veterans*
Authors: Ioana Danciu, Samantha Erwin, Greeshma Agasthya, Tate Janet, Benjamin McMahon, Georgia Tourassi, Amy Justice
Abstract: e17554

**Publication Only - Gastrointestinal Cancer—Colorectal and Anal**
*Microsatellite instability and KRAS mutation in stage 4 CRC: prevalence, geographic discrepancies and outcomes from the National Cancer Database*
Authors: Johannes Uhlig, Michael Cecchini, Stacey Stein, Jill Lacy, Kevin Kim
Abstract: e16052

**Publication Only - Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**
*PD-1 targeted immunotherapy for advanced hepatocellular cancer: Current utilization and outcomes in the United States*
Authors: Johannes Uhlig, Stacey Stein, Kevin Kim
Abstract: e16647

**Publication Only - Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**
*Efficacy of telotristat ethyl: A peripheral tryptophan hydroxylase inhibitor that blocks serotonin biosynthesis against cultured liposarcoma, colon cancer, and cholangiocarcinoma cell lines*
Authors: Harvey J. Kliman, Ivy S Ling, Kristin M Milano
Abstract: e15602

**Publication Only - Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology**
*Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist*
Authors: Monica Motwani, Dimple Modi, Sudhir Penugonda, Chun Zhang, Joann Palma, Alexis Cunningham, Emiliano Calvo, Maja J.A. de Jonge, Patricia LoRusso
Abstract: e15668

**Publication Only - Symptoms and Survivorship**
*Impact of breast cancer chemotherapy on ovarian damage and recovery*
Authors: Shari Beth Goldfarb, Giuliano Bedoschi, Volkan Turan, Angelena Crown, Nadia Abdo, Maura N. Dickler, Kutluk Oktay
Abstract: e24059
**Publication Only - Gynecologic Cancer**

**Malignant MIXED mullerian tumors and serous endometrial cancer: Molecular targets the need of the hour**
Authors: Manan Shah, Sanjay R Jain, Gabriela Oprea, **Saba Shafi**
Abstract: e18106

**Publication Only - Gynecologic Cancer**

**Prognostic significance of hormone receptor (ER/PR) status in endometrial carcinoma in black women: Implications with lymph node metastasis**
Authors: Manan Shah, Sanjay R Jain, Gabriela Oprea, **Saba Shafi**
Abstract: e18099

**Publication Only – Genitourinary Cancer—Prostate, Testicular, and Penile**

**Predicting prostate cancer death among 98,994 veterans: Differences by race/ethnicity**
Authors: **Janet Tate**, Ioana Danciu, Amy Justice, Michael Leapman, Benjamin McMahon, **Roxanne Wadia**
Abstract: e17609

**Publication Only - Genitourinary Cancer—Kidney and Bladder**

**Minimally invasive partial nephrectomy versus percutaneous cryoablation for stage Ia renal cell carcinoma: A cost-effectiveness analysis**
Authors: **Xiao Wu**, Johannes Uhlig, Brian M. Shuch, **Kevin Kim**
Abstract: e17066

**Publication Only - Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers**

**Thermal ablation versus stereotactic body radiotherapy for stage I non-small cell lung cancer: A cost-effectiveness analysis**
Authors: **Xiao Wu**, Johannes Uhlig, Justin Blasberg, Scott N. Gettinger, Robert Suh, Stephen Barnett Solomon, **Kevin Kim**
Abstract: e21061

**Publication Only - Health Services Research and Quality Improvement**

**Utilization of next-generation sequencing and associated systemic therapy initiation in metastatic prostate cancer**
Authors: **Daniel X. Yang**, Michael Leapman, Cary Philip Gross, **James B. Yu**
Abstract: e19308

**Publication Only - Health Services Research and Quality Improvement**

**Use of prophylactic cranial irradiation in patients with extensive-stage small cell lung cancer receiving immunotherapy**
Authors: **Daniel X. Yang**, Vikram Jairam, Henry S. Park, Roy H. Decker, Anne C. Chiang, Cary Philip Gross, **James B. Yu**
Abstract: e19309
Oral Sessions

**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**
*Hitting the Bullseye: Evolving Role of Targeted and Immune Therapy in Gastroesophageal Cancers*
Discussant: Barbara Burtness, MD
Session: May 30; 11:00 AM

**Cancer Prevention, Risk Reduction, and Genetics Highlights**
*Cancer Prevention, Risk Reduction, and Genetics*
Discussant: Erin Wysong Hofstatter, MD, Yale Cancer Center
Session: May 30; 2:30 PM

**Lung Cancer—Non-Small Cell Metastatic**
*IO/IO How Far Do We Go?*
Discussant: Scott N. Gettinger, MD | Yale Cancer Center
Session: May 31; 10:00 AM

**Care Delivery and Regulatory Policy**
*Man Versus Machine: Is Artificial Intelligence Ready for Clinical Practice?*
Discussant: Sanjay Aneja, MD | Department of Therapeutic Radiology, Yale School of Medicine
Session: May 31; 4:00 PM

**Steps Forward and Lessons Learned: Using Biomarkers to Guide Targeted Therapies in Breast Cancer, The Dr. Bernard Fisher Memorial Annual Clinical Science Symposium supported by the Breast Cancer Research Foundation®.**
*A Deep Dive Into Preoperative HER2 Biomarkers*
Discussant: Lajos Pusztai, MD, PhD | Yale Cancer Center

**Professional Development and Education Advances**
*Burnout Is Universal: It’s Not Just a Problem for American Physicians*
Discussant: Tara B. Sanft, MD | Yale School of Medicine

**Learning from the Biology: Advances in Endometrial and Ovarian Cancer**
*Uterine Serous Cancer: Expanding Targets*
Discussant: Alessandro Santin, MD | Yale University School of Medicine
**Head and Neck Cancer**

*Pembrolizumab (P) or P + chemotherapy (C) versus EXTREME (E) as first-line (1L) therapy for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC): analysis of KEYNOTE-048 by disease state*

Authors: Danny Rischin, Kevin Joseph Harrington, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto Castro, Amanda Psyrri, Neus Baste, Prakash C. Neupane, Åse Bratland, Thorsten Fuereder, Brett Gordon Maxwell Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, **Barbara Burtness**

Abstract: 6530
Poster: 191
Session: May 30; 10:30 AM

**Head and Neck Cancer**

*Correlation of tumor mutational burden (TMB) with CDKN2A and TP53 mutation in HPV-negative head and neck squamous cell carcinoma (HNSCC)*


Abstract: 6552
Poster: 213
Session: May 30; 10:30 AM

**Breast Cancer—Local/Regional/Adjuvant**

*Adherence to extended adjuvant endocrine therapy following Breast Cancer Index (BCI) testing in women with early-stage hormone receptor (HR)-positive breast cancers*

Authors: **Julia Foldi**, Catherine A. Schnabel, Max Salganik, Lajos Pusztai, **Tara B. Sanft**

Abstract: 527
Poster: 19
Session: May 30; 10:30 AM

**Breast Cancer—Metastatic**

*Preliminary efficacy data of triple-negative breast cancer cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors*


Abstract: 1077
Poster: 162
Session: May 30; 10:30 AM
**Breast Cancer—Metastatic**

*Trial in progress: A phase II open-label, randomized study of PARP inhibition (olaparib) either alone or in combination with anti-PD-L1 therapy (atezolizumab) in homologous DNA repair (HDR) deficient, locally advanced or metastatic non-HER2-positive breast cancer*

Authors: Patricia LoRusso, Mary Josephine P. Pilat, Cesar A. Santa-Maria, Roisin M. Connolly, Erin E. Roesch, Anosheh Afghahi, Hyo S. Han, Rita Nanda, Gerburg M. Wulf, Hadeel Assad, Haeseong Park, Elizabeth C. Dees, Jeremy M. Force, Anne M. Noonan, Adam Brufsky, Vandana G. Abramson, Barbara B. Haley, Saundra S. Buys, Elad Sharon, Kurt A. Schalper

Abstract: TPS1102
Poster: 187
Session: May 30; 10:30 AM

**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**

*The association of molecular biomarkers with efficacy of pembrolizumab versus paclitaxel in patients with gastric cancer (GC) from KEYNOTE-061*

Authors: Charles S. Fuchs, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-hee Ryu, Caterina Vivaldi, Tomasz Olesinski, Christian Caglevic, Hyun C. Chung, Kei Muro, Eric Van Cutsem, Julie Kobie, Razvan Cristescu, Deepti Aurora-Garg, Jia Lu, Chie-Schin Shih, David E. Adelberg, Z. Alexander Cao, Kohei Shitara

Abstract: 4512
Poster: 120
Session: May 30; 11:00 AM

**Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary**

*The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061*

Authors: Kohei Shitara, Mustafa Özgüroğlu, Yung-Jue Bang, Maria Di Bartolomeo, Mario Mandalà, Min-hee Ryu, Caterina Vivaldi, Tomasz Olesinski, Hyun Cheol Chung, Kei Muro, Eric Van Cutsem, Julie Kobie, Razvan Cristescu, Deepti Aurora-Garg, Jia Lu, Chie-Schin Shih, David Adelberg, Z. Alexander Cao, David Fabrizio, Charles S. Fuchs

Abstract: 4537
Poster: 145
Session: May 30; 11:00 AM

**Hematologic Malignancies—Plasma Cell Dyscrasia**

*Efficacy of daratumumab in the treatment of multiple myeloma with high-risk cytogenetics: Meta-analysis of randomized phase III trials*

Authors: Smith Giri, Alyssa Grimshaw, Susan Bal, Kelly Nicole Godby, Prakash Kharel, Benjamin Djulbegovic, Saad Zafar Usmani, Thierry Facon, Philippe Moreau, Meletios A. Dimopoulos, Maria-Victoria Mateos, Luciano J. Costa

Abstract: 8540
Poster: 440
Session: May 30; 11:30 AM
**Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant**

*Clinical benefit of luspatercept in patients (pts) with lower-risk MDS (LR-MDS) and high transfusion burden in the phase III MEDALIST study*


Abstract: 7554
Poster: 327

**Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant**

*Glasdegib in combination with azacitidine (AZA) in patients (pts) with untreated higher-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and chronic myelomonocytic leukemia (CMML): Effects on marrow recovery and transfusion independence*

Authors: **Amer M. Zeidan**, Michael Schuster, Magalie Joris, Jurgen Krauter, Johan Maertens, Emmanuel Gyan, Tibor Kovacsovsics, Amit Verma, Paresh Vyas, Eunice S. Wang, Wendy Ma, Mirjana Zeremski, Art Kudla, Geoffrey Chan, Mikkael A. Sekeres

Abstract: 7526
Poster: 299
Session: May 30; 11:30 AM

**Gynecologic Cancer**

*Sacituzumab govitecan (SG) in patients (pts) with previously treated metastatic endometrial cancer (mEC): results from a phase III study*

Authors: **Alessandro Santin**, Takefumi Komiya, David M. Goldenberg, Robert M. Sharkey, Quan Hong, William A. Wegener, Trishna Goswami, Aditya Bardia

Abstract: 6081
Poster: 252
Session: May 30; 11:30 AM

**Symptoms and Survivorship**

*Long-term cancer survival in cohorts of U.S. health professionals*

Authors: **En Cheng**, Donghoon Lee, Rulla M Tamimi, Susan Hankinson, Walter C Willett, Edward L. Giovannucci, Heather Eliassen, Shelley Tworoger, Stampfer Meir, Lorelei A. Mucci, Charles S. Fuchs, **Donna Spiegelman**

Abstract: 12075
Poster: 363
Session: May 30; 2:30PM

**Symptoms and Survivorship**

*Temporal trends in opioid prescribing patterns among oncologists in the Medicare population*

Authors: **Vikram Jairam**, Daniel X. Yang, Saamir Pasha, Pamela R. Soulos, Cary Philip Gross, James B. Yu, **Henry Soo-Min Park**

Abstract: 12022
Poster: 310
Session: May 30; 2:30 PM
Symptoms and Survivorship
Aggressive care at end-of-life in the Veteran’s Health Administration versus fee-for-service Medicare among patients with advanced lung cancer
Authors: Carolyn J. Presley, Kiranveer Kaur, Ling Han, Pamela R. Soulos, Weiwei Zhu, Emily Corneau, John R. O’Leary, Herta H. Chao, Tracy Shamas, Michal G. Rose, Karl Lorenz, Cari Levy, Vincent Mor, Cary P. Gross
Abstract: 12025
Poster: 313
Session: May 30; 2:30 PM

Symptoms and Survivorship
The adoption of immune checkpoint inhibitors and patterns of care at the end of life
Authors: Fauzia Riaz, Geliang Gan, Fangyong Li, Amy J. Davidoff, Kerin B. Adelson, Carolyn J. Presley, Blythe J. Adamson, Pooja Shaw, Ravi B. Parikh, Ronac Mamtani, Cary P. Gross
Abstract: 12027
Poster: 315
Session: May 30; 2:30 PM

Health Services Research and Quality Improvement
NSCLC: Integrating the “Yale model shared decision-making solution” into the practice setting
Authors: Kerin B. Adelson, Roy S. Herbst, Patricia Peterson, Michele Ingram, Brant J. Oliver, Tarjani Agrawal, Marianne Davies, Elaine Rudell
Abstract: 7054
Poster: 32
Session: May 31; 9:30 AM

Lung Cancer—Non-Small Cell Metastatic
PD-L1 tumor proportion score and clinical benefit from first-line pembrolizumab in patients with advanced nonsquamous versus squamous non-small cell lung cancer (NSCLC).
Authors: Deborah B. Doroshow, Wei Wei, Jon Zugazagoitia, Charles J. Robbins, Swati Gupta, Blythe J. Adamson, David L. Rimm
Abstract: 9539
Poster: 305
Session: May 31; 10:00 AM

Lung Cancer—Non-Small Cell Metastatic
Lung-MAP (SWOG S1400): Design, implementation, and lessons learned from a biomarker-driven master protocol (BDMP) for previously-treated squamous lung cancer (sqNSCLC).
Abstract: 9576
Poster: 342
Session: May 31; 10:00 AM
**Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers**

Preliminary efficacy data of platinum-pretreated small cell lung cancer (SCLC) cohort of NCI 9881 study: A phase II study of cediranib in combination with olaparib in advanced solid tumors


Abstract: 9065
Poster: 258
Session: May 31; 10:00 AM

**Lung Cancer—Non-Small Cell Metastatic**

Comparative efficacy of chemoimmunotherapy versus immunotherapy alone in the front-line treatment of advanced non-small cell lung cancer: A systematic review and network meta-analysis.

Authors: Ranjan Pathak, Gilberto Lopes, Han Yu, Wenyan Ji, Madan Aryal, Katherine Stemmer Frumento, Christopher J.D. Wallis, Zachary William Abraham Klaassen, Henry Soo-Min Park, Sarah B. Goldberg

Abstract: 9552
Poster: 318
Session: May 31; 10:00 AM

**Pediatric Oncology**

Neuromuscular dysfunction and associated health/socioeconomic outcomes: A report from the Childhood Cancer Survivor Study (CCSS)


Abstract: 10546
Poster: 433
Session: May 31; 10:00 AM

**Pediatric Oncology**

Peripheral motor and sensory neuropathy in survivors of childhood central nervous system (CNS) tumors in the St. Jude Lifetime (SJLIFE) cohort


Abstract: 10549
Poster: 436
Session: May 31; 10:00 AM
Genitourinary Cancer—Kidney and Bladder

Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitecan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy

Authors: Daniel P. Petrylak, Scott T. Tagawa, Rohit K. Jain, Manojkumar Bupathi, Arjun V. Balar, Arash Rezazadeh, Saby George, Phillip L. Palmbos, Luke T. Nordquist, Nancy B. Davis, Nicholas J. Vogelzang, Chethan Ramamurthy, Cora N. Sternberg, Yohann Loriot, Neeraj Agarwal, Quan Hong, Allison Gladden, Charu Kanwal, Trishna Goswami, Petros Grivas

Abstract: 5027
Poster: 96
Session: May 31; 3:30 PM

Developmental Therapeutics—Immunotherapy

Immune profiling and clinical outcomes in patients treated with ramucirumab and pembrolizumab in phase I study JVD

Authors: Roy S. Herbst, Hendrik-Tobias Arkenau, Emiliano Calvo, Johanna C. Bendell, Nicolas Penel, Charles S. Fuchs, Samuel McNeely, Erik R. Rasmussen, Hong Wang, Joana M. Oliveira, David R. Ferry, Ian Chau

Abstract: 3089
Poster: 153
Session: May 31; 4:00 PM

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Increased tumor purity and improved biomarker detection using precision needle punch enrichment of pathology specimen paraffin blocks: Method validation and implementation in a prospective clinical trial

Authors: Jonathan Keith Killian, Chris Wright, Lindsay Chan, Natalie Danziger, Julia Andrea Elvin, Jo-Anne Vergilio, Douglas I. Lin, Erik Abraham Williams, Shakti H. Ramkisson, Eric Allan Severson, Amanda Hemmerich, Daniel Duncan, Claire I. Edgerly, Julie Y Tse, Kimberly McGregor, Alexa Betzig Schrock, Brian Michael Alexander, Jeffrey S. Ross, Mary Weber Redman, Roy S. Herbst

Abstract: 3622
Poster: 352
Session: May 31; 4:00 PM

Care Delivery and Regulatory Policy

Model selection applied to 750 outpatient ICD-9 codes identifies hazards important for all-cause cancer mortality in 2 million veterans with 14 years of follow-up

Authors: Benjamin McMahon, Sayera Dhaubhadel, Nicolas Hengartner, Ioana Danciu, Janet Tate, Amy Justice

Abstract: 2053
Poster: 45
Session: May 31; 4:00 PM
Genitourinary Cancer—Kidney and Bladder

Early results of TROPHY-U-01 Cohort 2: Sacituzumab govitcan (SG) in platinum-ineligible patients (pts) with metastatic urothelial cancer (mUC) who progressed after prior checkpoint inhibitor (CPI) therapy

Authors: Daniel P. Petrylak, Scott T. Tagawa, Rohit K. Jain, Manojkumar Bupathi, Arjun V. Balar, Arash Rezazadeh, Saby George, Phillip L. Palmbos, Luke T. Nordquist, Nancy B. Davis, Nicholas J. Vogelzang, Chethan Ramamurthy, Cora N. Sternberg, Yohann Loriot, Neeraj Agarwal, Quan Hong, Allison Gladden, Charu Kanwal, Trishna Goswami, Petros Grivas

Abstract: 5027
Poster: 96
Session: May 31; 3:30 PM

Professional Development and Education Advances

Delivery of cancer survivorship education to community health care professionals

Authors(s): Ashley Pariser, Javin Brita, Maura Harrigan, Scott Capozza, Angela Khairallah, Tara B. Sanft

Abstract: 11032
Poster: 289

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

TROPiCS–03: A phase II open-label study of sacituzumab govitcan (SG) in patients with metastatic solid tumors

Authors: Ashish Saxena, Loren S. Michel, Quan Hong, Karrie Hilsinger, Charu Kanwal, Cabilia Pichardo, Trishna Goswami, Alessandro Santin

Abstract: TPS3648
Poster: 378
Session: May 31; 4:00 PM

Developmental Therapeutics—Immunotherapy

Phase II trial of Voyager-V1 (vesicular stomatitis virus expressing human IFNβ and NIS, VV1), in combination with cemiplimab (C) in patients with NSCLC, melanoma, HCC or endometrial carcinoma


Abstract: TPS3161
Poster: 225
Session: May 31; 4:00 PM